HomeCompareEIGRQ vs PLD

EIGRQ vs PLD: Dividend Comparison 2026

EIGRQ yields 23.53% · PLD yields 3.10%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PLD wins by $5.82M in total portfolio value· pulled ahead in Year 6
10 years
EIGRQ
EIGRQ
● Live price
23.53%
Share price
$8.50
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$90.5K
Annual income
$9,663.72
Full EIGRQ calculator →
PLD
PLD
● Live price
3.10%
Share price
$132.18
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.91M
Annual income
$4,750,725.19
Full PLD calculator →

Portfolio growth — EIGRQ vs PLD

📍 PLD pulled ahead of the other in Year 6

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEIGRQPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EIGRQ + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EIGRQ pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EIGRQ
Annual income on $10K today (after 15% tax)
$2,000.00/yr
After 10yr DRIP, annual income (after tax)
$8,214.16/yr
PLD
Annual income on $10K today (after 15% tax)
$263.66/yr
After 10yr DRIP, annual income (after tax)
$4,038,116.41/yr
At 15% tax rate, PLD beats the other by $4,029,902.25/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EIGRQ + PLD for your $10,000?

EIGRQ: 50%PLD: 50%
100% PLD50/50100% EIGRQ
Portfolio after 10yr
$3.00M
Annual income
$2,380,194.45/yr
Blended yield
79.36%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

EIGRQ
No analyst data
Altman Z
-24.3
Piotroski
4/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+2.9% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EIGRQ buys
0
PLD buys
0
No recent congressional trades found for EIGRQ or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEIGRQPLD
Forward yield23.53%3.10%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$90.5K$5.91M
Annual income after 10y$9,663.72$4,750,725.19
Total dividends collected$55.7K$5.78M
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: EIGRQ vs PLD ($10,000, DRIP)

YearEIGRQ PortfolioEIGRQ Income/yrPLD PortfolioPLD Income/yrGap
1$13,053$2,352.94$11,241$540.96+$1.8KEIGRQ
2$16,837$2,870.36$13,019$991.13+$3.8KEIGRQ
3$21,476$3,460.26$15,801$1,870.97+$5.7KEIGRQ
4$27,104$4,124.87$20,609$3,701.21+$6.5KEIGRQ
5$33,867$4,865.30$29,919$7,867.97+$3.9KEIGRQ
6← crossover$41,919$5,681.51$50,631$18,617.74$8.7KPLD
7$51,425$6,572.30$105,528$51,352.20$54.1KPLD
8$62,561$7,535.33$287,364$174,449.42$224.8KPLD
9$75,507$8,567.24$1,081,760$774,280.77$1.01MPLD
10$90,456$9,663.72$5,908,209$4,750,725.19$5.82MPLD

EIGRQ vs PLD: Complete Analysis 2026

EIGRQStock

Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development of therapies for hepatitis delta virus (HDV) and other serious diseases. The company offers Zokinvy for the treatment of Hutchinson-Gilford progeria syndrome and Processing-Deficient Progeroid Laminopathies. Its product candidates include Lonafarnib, an orally available, farnesylation inhibitor, which has completed Phase 3 clinical trials for HDV infection; Peginterferon Lambda (lambda), which is in clinical development for HDV; lambda, that is in phase II and III investigator studies of mild and moderate COVID-19; and Avexitide, which is in Phase II for the treatment of congenital hyperinsulinism and post-bariatric hypoglycemia. The company is headquartered in Palo Alto, California. On April 1, 2024, Eiger BioPharmaceuticals, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Northern District of Texas.

Full EIGRQ Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this EIGRQ vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EIGRQ vs SCHDEIGRQ vs JEPIEIGRQ vs OEIGRQ vs KOEIGRQ vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.